Lipoprotein Lipase Mutations, Plasma Lipids and Lipoproteins, and Risk of Ischemic Heart Disease A Meta-Analysis

Background —We assessed in meta-analyses the effect of the Gly188Glu, Asp9Asn, Asn291Ser, and Ser447Ter substitutions in lipoprotein lipase in the heterozygous state on lipid metabolism and risk of ischemic heart disease (same order used below). Methods and Results —In 29 separate studies, 20 903 white subjects were screened for ≥1 of these substitutions; each meta-analysis included only some of these individuals. In population-based studies, heterozygote frequencies ranged from 0.04% to 0.2%, 2% to 4%, 1% to 7%, and 17% to 22% for the respective substitutions. Postheparin plasma lipoprotein lipase activity decreased 53% (95% CI, 31% to 75%) (only 1 study), 30% (22% to 37%), and 22% (8% to 35%) and was unchanged at 4% (−10% to 19%), respectively. Plasma triglycerides increased 78% (95% CI, 64% to 92%), 20% (9% to 33%), and 31% (20% to 43%) and decreased 8% (4% to 11%), respectively. HDL cholesterol decreased 0.25 mmol/L (0.18 to 0.32), 0.08 mmol/L (0.04 to 0.12), and 0.12 mmol/L (0.10 to 0.15) and increased 0.04 mmol/L (0.02 to 0.06), respectively. Odds ratios for ischemic heart disease were 4.9 (95% CI, 1.2 to 20) (only 1 study), 1.4 (0.8 to 2.4), 1.2 (0.9 to 1.5), and 0.8 (0.7 to 1.0), respectively. Subgroup analysis indicated that women with the Asn291Ser substitution may have an increased risk of ischemic heart disease. Conclusions —These meta-analyses suggest that compared with noncarriers, carriers of the Gly188Glu, Asp9Asn, and Asn291Ser substitutions have an atherogenic lipoprotein profile, whereas carriers of the Ser447Ter substitution have a protective lipoprotein profile. Accordingly, risk of ischemic heart disease in heterozygous carriers is increased for Gly188Glu carriers; at most, the increase is borderline for Asp9Asn and Asn291Ser carriers; and risk is possibly decreased for Ser447Ter carriers.

[1]  S. Humphries,et al.  Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. , 1997, Atherosclerosis.

[2]  M. Taskinen,et al.  The Asn‐291→Ser and Ser‐477→Stop mutations of the lipoprotein lipase gene and their significance for lipid metabolism in patients with hypertriglyceridaemia , 1997, European journal of clinical investigation.

[3]  P. Talmud,et al.  A common mutation in the lipoprotein lipase gene promoter, -93T/G, is associated with lower plasma triglyceride levels and increased promoter activity in vitro. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[4]  G. Jensen,et al.  Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. , 1997, Circulation.

[5]  J. Boer,et al.  Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and postprandial states: the European Atherosclerosis Research Studies. , 1997, Circulation.

[6]  E. Boerwinkle,et al.  Genetic Variant Showing a Positive Interaction With β-Blocking Agents With a Beneficial Influence on Lipoprotein Lipase Activity, HDL Cholesterol, and Triglyceride Levels in Coronary Artery Disease Patients: The Ser447-Stop Substitution in the Lipoprotein Lipase Gene , 1997 .

[7]  G. Siest,et al.  Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. , 1997, Journal of lipid research.

[8]  P. Schnohr,et al.  A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. , 1997, The Journal of clinical investigation.

[9]  E. Boerwinkle,et al.  Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. , 1997, Circulation.

[10]  J. Hokanson.  Lipoprotein lipase gene variants and risk of coronary disease: a quantitative analysis of population-based studies , 1997, International journal of clinical & laboratory research.

[11]  E. Stein,et al.  Higher triglycerides, lower high-density lipoprotein cholesterol, and higher systolic blood pressure in lipoprotein lipase-deficient heterozygotes. A preliminary report. , 1996, Circulation.

[12]  A. Zwinderman,et al.  The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. , 1996, Circulation.

[13]  M. Hayden,et al.  Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. , 1996, The New England journal of medicine.

[14]  P. Talmud,et al.  Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia , 1996, European journal of clinical investigation.

[15]  M. Hayden,et al.  A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postprandial chylomicron triglyceride and retinyl palmitate response in normolipidemic carriers. , 1996, Journal of lipid research.

[16]  D. Galton,et al.  Identification of putative beneficial mutations for lipid transport. , 1996, Zeitschrift fur Gastroenterologie.

[17]  S. Humphries,et al.  Association between the LPL-D9N mutation in the lipoprotein lipase gene and plasma lipid traits in myocardial infarction survivors from the ECTIM Study. , 1996, Atherosclerosis.

[18]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[19]  M. Taskinen,et al.  Heterozygosity for Asn291-->Ser mutation in the lipoprotein lipase gene in two Finnish pedigrees: effect of hyperinsulinemia on the expression of hypertriglyceridemia. , 1996, Journal of lipid research.

[20]  P. de Knijff,et al.  The lipoprotein lipase (Asn291-->Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia. , 1996, Atherosclerosis.

[21]  P. Julien,et al.  Molecular pathobiology of the human lipoprotein lipase gene. , 1996, Pharmacology & therapeutics.

[22]  W. Marz,et al.  Common genetic variants of lipoprotein lipase that relate to lipid transport in patients with premature coronary artery disease , 1995, Clinical genetics.

[23]  M. Hayden,et al.  Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291-->Ser mutation in the human LPL gene. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[24]  D. Gaudet,et al.  Mutations in the gene for lipoprotein lipase. A cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[25]  D. Kromhout,et al.  A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. , 1995, Human molecular genetics.

[26]  Common Genetic Determinants of Dyslipidemia: The Hypertriglyceridemia/Low‐High-Density Lipoprotein Syndrome , 1995, Journal of cardiovascular pharmacology.

[27]  S. Deeb,et al.  A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Humphries,et al.  A common variant in the gene for lipoprotein lipase (Asp9→Asn) : functional implications and prevalence in normal and hyperlipidemic subjects , 1995 .

[29]  R. Wootton,et al.  Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[30]  A. Hamsten,et al.  Interaction of the lipoprotein lipase asparagine 291-->serine mutation with body mass index determines elevated plasma triacylglycerol concentrations: a study in hyperlipidemic subjects, myocardial infarction survivors, and healthy adults. , 1995, Journal of lipid research.

[31]  M. Hayden,et al.  A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis , 1995, Nature Genetics.

[32]  D. Arveiler,et al.  Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Témoin sur l'Infarctus du Myocarde. , 1995, Journal of lipid research.

[33]  J. Lalouel,et al.  Molecular screening of the lipoprotein lipase gene in hypertriglyceridemic members of familial noninsulin-dependent diabetes mellitus families. , 1994, The Journal of clinical endocrinology and metabolism.

[34]  P. Elwood,et al.  DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[35]  P. Barter,et al.  High-density lipoproteins and coronary heart disease. , 1991, Journal of cardiovascular risk.

[36]  S. Humphries,et al.  Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. , 1992, Atherosclerosis.

[37]  D. Galton,et al.  Lipoprotein lipase genotypes for a common premature termination codon mutation detected by PCR-mediated site-directed mutagenesis and restriction digestion. , 1992, Journal of lipid research.

[38]  M. Sippl,et al.  Molecular basis of lipoprotein lipase deficiency in two Austrian families with type I hyperlipoproteinemia. , 1991, Atherosclerosis.

[39]  M. Emi,et al.  Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. , 1990, The Journal of clinical investigation.

[40]  F Mosteller,et al.  Some Statistical Methods for Combining Experimental Results , 1990, International Journal of Technology Assessment in Health Care.

[41]  J. Brunzell.  Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome , 1989 .

[42]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.